The CA 19-9 test measures the concentration of carbohydrate antigen 19-9, a tumor-associated mucin protein, in the bloodstream. It is primarily utilized as a vital serum biomarker to monitor disease progression, evaluate treatment efficacy, and detect potential recurrence in patients diagnosed with pancreatic cancer. Because levels can also be elevated in other gastrointestinal malignancies, such as cholangiocarcinoma or colorectal cancer, as well as benign conditions like biliary obstruction or pancreatitis, the test is not recommended as a standalone screening tool. Instead, clinicians integrate CA 19-9 results alongside imaging studies and clinical evaluations for comprehensive oncological management.